Skip to main content

Day: October 31, 2021

Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C

Orphazyme A/SCompany announcement        No. 24/2021Inside informationCompany Registration No. 32266355Progress made in understanding potential resolution of topics outlined in Complete Response Letter, including need for additional data to support NDA FDA recommends the company provides supplemental information and analyses, and the FDA offers to have further interactions to identify a path to resubmission for arimoclomol in NPCCopenhagen – October 31, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today provides an update on the regulatory status in the United States of its investigational product arimoclomol for Niemann-Pick disease type C (NPC) following a recently held Type A meeting with the U.S. Food and Drug Administration (FDA). The Company had a collaborative dialogue with the FDA during...

Continue reading

Alm. Brand A/S completes capital reduction by changing share denomination

Announcement no. 31/2021 Alm. Brand A/S completes capital reduction by changing share denomination At the extraordinary general meeting of Alm. Brand A/S held on 2 September 2021, the shareholders resolved to reduce the company’s share capital by nominally DKK 1,387,026,000 from nominally DKK 1,541,140,000 to nominally DKK 154,114,000 at par value for allocation to distributable reserves under equity. As the company has not received any claims during the statutory claims filing period, the capital reduction has now been finally registered in the computer systems of the Danish Business Authority. The capital reduction was completed by changing the denomination of the company’s shares from DKK 10 per share to DKK 1 per share. The capital reduction does not change the number of shares. With reference to section 32 of the Capital Markets...

Continue reading

Skeljungur hf.: Conditions removed regarding financing and due diligence relating to the sale of P/F Magn to Sp/f Orkufelagið. Skeljungur plans to invest up to 23% of the total selling price of P/F Magn in Sp/f Orkufelagið.

It was announced last 2 September that Skeljungur had made a decision to enter into exclusive negotiations with Sp/f Orkufelagið on the sale of all the shares in Skeljungur’s subsidiary in the Faroe Islands, P/F Magn, based on an offer to buy made by Sp/f Orkufelagið.  Sp/f Orkufelagið has now declared to Skeljungur that reservations regarding financing and due diligence have either been satisfied or waived. The selling price of P/F Magn remains unchanged from the amount announced earlier, i.e. 615 million DKK, or 12.3 billion ISK. Skeljungur has decided to participate in the funding of Sp/f Orkufelagið by re-investing up to 23% of the total proceeds from the transaction in Sp/f Orkufelagið and consequently Skeljungur will own up to 49% stake in Sp/Orkufelagið. Accordingly, the estimated impact of the transaction on Skeljungur’s financial...

Continue reading

UPP Olaines OÜ consolidated unaudited financial results for Q3 and 9 months of 2021

MANAGEMENT REPORT FOR 9 MONTHS 2021 General information UPP Olaines OÜ (hereafter ‘the Company’ and ‘the Group’ when referred together with subsidiaries) was established for the purpose of funding, acquiring and managing the real estate investment of Olaines Logistics Park: (buildings and land) located at “Šarlotes”, Olaines county, Olaines parish, Latvia, cadastre number 8080 003 0029, registered in the Land Register compartment No.5439 of the city of Olaine parish. The Company was established on 24.08.2017 and had no economic activity until 15.12.2017, when it acquired the cold storage warehouse Olaines Logistics Park. The management board is aware of no trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on the Company’s prospects for the period after the reporting period of these...

Continue reading

ESA signs contract with Danish Aerospace Company A/S for an extra E4D

COMPANY ANNOUNCEMENT Odense, October 31st, 2021 Company Announcement no. 31 – 31-10-2021         ESA signs contract with Danish Aerospace Company A/S for an extra E4D Danish Aerospace Company A/S (DAC) has now signed the contract with ESA for an additional E4D model and more spares. This happened after formally being requested to make an offer for yet another flight model of the company’s future E4D-multifunction exercise equipment back in June of this year. (DAC Company Announcement no. 27). This contract now ensures ESA and NASA will have a full spare flight model available on ground when the equipment will be launched and become part of the standard complement of exercise equipment for the astronauts on the International Space Station ISS.DAC is now contracted to develop two flight- and three ground models of the new multifunction/crosstrainer...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.